PL328916A1 - Compositions containing inhibitors of hiv protease, such as vx 478 and water-soluble vitamin e compound such as vitamin e-tpgs - Google Patents

Compositions containing inhibitors of hiv protease, such as vx 478 and water-soluble vitamin e compound such as vitamin e-tpgs

Info

Publication number
PL328916A1
PL328916A1 PL97328916A PL32891697A PL328916A1 PL 328916 A1 PL328916 A1 PL 328916A1 PL 97328916 A PL97328916 A PL 97328916A PL 32891697 A PL32891697 A PL 32891697A PL 328916 A1 PL328916 A1 PL 328916A1
Authority
PL
Poland
Prior art keywords
vitamin
tpgs
compound
water
compositions containing
Prior art date
Application number
PL97328916A
Other versions
PL187919B1 (en
Inventor
Arup K Roy
Lloyd Gary Tillman
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9606372.2A external-priority patent/GB9606372D0/en
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of PL328916A1 publication Critical patent/PL328916A1/en
Publication of PL187919B1 publication Critical patent/PL187919B1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
PL32891697A 1996-03-22 1997-03-21 Compositions containing inhibitors of hiv protease, such as vx 478 and water-soluble vitamin e compound such as vitamin e-tpgs PL187919B1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US1389396P 1996-03-22 1996-03-22
GBGB9606372.2A GB9606372D0 (en) 1996-03-26 1996-03-26 Pharmaceutical formulations
PCT/EP1997/001438 WO1997035587A1 (en) 1996-03-22 1997-03-21 Compositions comprising an hiv protease inhibitor such as vx 478 and a water soluble vitamin e compound such as vitamin e-tpgs

Publications (2)

Publication Number Publication Date
PL328916A1 true PL328916A1 (en) 1999-03-01
PL187919B1 PL187919B1 (en) 2004-11-30

Family

ID=26308992

Family Applications (1)

Application Number Title Priority Date Filing Date
PL32891697A PL187919B1 (en) 1996-03-22 1997-03-21 Compositions containing inhibitors of hiv protease, such as vx 478 and water-soluble vitamin e compound such as vitamin e-tpgs

Country Status (12)

Country Link
JP (1) JP3117726B2 (en)
AR (1) AR006345A1 (en)
BG (1) BG64457B1 (en)
CO (1) CO4790151A1 (en)
HU (1) HU228026B1 (en)
ID (1) ID16781A (en)
IL (1) IL126185A (en)
MY (1) MY126358A (en)
OA (1) OA10880A (en)
PL (1) PL187919B1 (en)
TW (1) TW455491B (en)
WO (1) WO1997035587A1 (en)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU730216B2 (en) * 1996-09-01 2001-03-01 Pharmos Corporation Solid coprecipitates for enhanced bioavailability of lipophilic substances
WO1998057648A1 (en) * 1997-06-16 1998-12-23 Vertex Pharmaceuticals Incorporated Methods of increasing the bioavailability of stable crystal polymorphs of a compound
US5891845A (en) * 1997-11-21 1999-04-06 Fuisz Technologies Ltd. Drug delivery systems utilizing liquid crystal structures
ES2140329B1 (en) * 1997-12-04 2000-10-16 Univ Granada USE OF MASLINIC ACID AS A PROTEASE INHIBITOR FOR THE TREATMENT OF DISEASE CAUSED BY THE VIRUSES OF ACQUIRED IMMUNODEFICIENCY.
GB9812189D0 (en) * 1998-06-05 1998-08-05 Glaxo Group Ltd Methods and compositions for increasing penetration of HIV protease inhibitors
CA2432527A1 (en) * 2000-12-22 2002-07-04 Takeda Chemical Industries, Ltd. Medicinal compositions for oral use
AU2002350719A1 (en) * 2002-11-29 2004-06-23 Janssen Pharmaceutica N.V. Pharmaceutical compositions comprising a basic respectively acidic drug compound, a surfactant and a physiologically tolerable water-soluble acid respectively base
US7423004B2 (en) 2003-01-31 2008-09-09 Smithkline Beecham Corporation Solid dispersion compositions
CA2578356C (en) * 2004-09-24 2013-05-28 Boehringer Ingelheim Pharmaceuticals, Inc. A new class of surfactant-like materials
JP2008514714A (en) * 2004-09-30 2008-05-08 イーストマン ケミカル カンパニー Pharmaceutical formulations containing vitamin ETPGS molecules solubilizing lipophilic drugs that do not exhibit significant spill inhibition and the use of such pharmaceutical formulations
EP1880715A1 (en) * 2006-07-19 2008-01-23 Abbott GmbH & Co. KG Pharmaceutically acceptable solubilizing composition and pharmaceutical dosage form containing same
SA109300195B1 (en) * 2008-03-28 2013-04-20 Astrazeneca Ab A Novel Anti-Cancer Pharmaceutical Composition
ITRM20120331A1 (en) 2012-07-12 2014-01-13 Guidotti & C Spa Labor LIQUID ORAL PEDIATRIC COMPOSITIONS CONTAINING NEPADUTANT.

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992016501A1 (en) * 1991-03-20 1992-10-01 Vertex Pharmaceuticals Incorporated Tetrahydroxyalkane derivatives as inhibitors of hiv aspartyl protease
EP0541168B1 (en) * 1991-11-08 1998-03-11 Merck & Co. Inc. HIV protease inhibitors useful for the treatment of aids
IS2334B (en) * 1992-09-08 2008-02-15 Vertex Pharmaceuticals Inc., (A Massachusetts Corporation) Aspartyl protease inhibitor of a new class of sulfonamides
WO1994013629A1 (en) * 1992-12-11 1994-06-23 Vertex Pharmaceuticals Incorporated Mannitol derivatives and their use as inhibitors of aspartyl protease
US5484926A (en) * 1993-10-07 1996-01-16 Agouron Pharmaceuticals, Inc. HIV protease inhibitors
DK0727419T3 (en) * 1992-12-29 2002-06-10 Abbott Lab Intermediates for the preparation of compounds that inhibit retroviral protease
AU6122994A (en) * 1993-01-15 1994-08-15 Agouron Pharmaceuticals, Inc. Hiv protease inhibitors and their preparation
AU1046895A (en) * 1993-11-05 1995-05-23 Merck & Co., Inc. New quinazolines as inhibitors of hiv reverse transcriptase
IL111584A0 (en) * 1993-11-18 1995-01-24 Merck & Co Inc Prodrugs of an inhibitor of hiv protease and pharmaceutical compositions containing them
CZ288312B6 (en) * 1993-12-15 2001-05-16 Merck & Co Inc HIV-protease inhibitors and pharmaceutical preparations in which they are comprised
AU699483B2 (en) * 1994-03-07 1998-12-03 Vertex Pharmaceuticals Incorporated Sulphonamide derivatives as aspartyl protease inhibitors
GB9409778D0 (en) * 1994-05-16 1994-07-06 Dumex Ltd As Compositions
US5527829A (en) * 1994-05-23 1996-06-18 Agouron Pharmaceuticals, Inc. HIV protease inhibitors
EP0825849A1 (en) * 1995-05-19 1998-03-04 Abbott Laboratories Self-emulsifying formulations of lipophilic drugs

Also Published As

Publication number Publication date
CO4790151A1 (en) 1999-05-31
WO1997035587A1 (en) 1997-10-02
HUP9901887A2 (en) 1999-12-28
HUP9901887A3 (en) 2000-02-28
ID16781A (en) 1997-11-13
HU228026B1 (en) 2012-08-28
OA10880A (en) 2001-10-11
AR006345A1 (en) 1999-08-25
TW455491B (en) 2001-09-21
IL126185A (en) 2003-05-29
IL126185A0 (en) 1999-05-09
JP3117726B2 (en) 2000-12-18
JP2000500504A (en) 2000-01-18
BG102838A (en) 1999-09-30
BG64457B1 (en) 2005-03-31
MY126358A (en) 2006-09-29
PL187919B1 (en) 2004-11-30

Similar Documents

Publication Publication Date Title
IL109503A0 (en) Hiv protease inhibitors and pharmaceutical compositions containing them
HUP0104768A3 (en) 4-amino-3-oxo-azepanes as protease inhibitors and pharmaceutical compositions containing the same
HUP9900964A3 (en) Protease inhibitors and pharmaceutical compositions containing these compounds
AU7294098A (en) Metalloproteinase inhibitors, pharmaceutical compositions containing them and their pharmaceutical uses
HUP0103283A3 (en) Pyrazinone protease inhibitors, pharmaceutical compositions containing them and use of the compounds
HUP0103575A3 (en) Inhibitors of caspases, pharmaceutical compositions comprising thereof and their use
HUP9702035A3 (en) Inhibitors of leukocita-adhesion- and vla-4-antagonists and pharmaceutical compositions containing them
HUP9702036A3 (en) Inhibitors of leucocita-adhesion and wla-4-antagonists and pharmaceutical compositions containing them
HUP0103806A2 (en) Serine protease inhibitor and pharmaceutical compositions containing them
HUP9702034A3 (en) Inhibitors of leukocita-adhesion and vla-4-antagonists and pharmaceutical compositions containing them
HUP0100186A3 (en) Compounds as lactam metalloprotease inhibitors and pharmaceutical compositions containing them
BG103425A (en) Pharmaceutical composition
HUP0201479A2 (en) Novel macrocyclic compounds as metalloprotease inhibitors and pharmaceutical compositions containing them
ZA971964B (en) Azolobenzazepine derivatives and compositions and method of use thereof.
PL328916A1 (en) Compositions containing inhibitors of hiv protease, such as vx 478 and water-soluble vitamin e compound such as vitamin e-tpgs
HUP0002951A3 (en) Bis-aminomethylcarbonyl compounds as protease inhibitors and pharmaceutical compositions containing them
PL320132A1 (en) Analogues of vitamin d3, method of obtaining them and pharmaceutic compositions containing them
AU5820294A (en) Endothelin converting enzyme inhibitors
IL120310A0 (en) Serine protease inhibitors and pharmaceutical compositions containing them
HUP0002853A3 (en) 6,7-asymmetrically disubstituted quinoxalinecarboxylic acid derivatives, and pharmaceutical compositions containing them
MA26486A1 (en) PROTEASE INHIBITOR ARYL- AND HETEROARYL-THIAZOLOCETOHYDRAZIDES, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM.
IL111584A0 (en) Prodrugs of an inhibitor of hiv protease and pharmaceutical compositions containing them
AU4505199A (en) Methods and compositions for increasing penetration of hiv protease inhibitors
IL117247A (en) Pharmaceutical compositions comprising protease inhibitors and quinoxalines
EP0983243A4 (en) Novel quinoline- and naphthalenecarboxamides, pharmaceutical compositions and methods of inhibiting calpain